Former Chief Legal Officer · Aclaris Therapeutics, Inc. (ACRS)

Kamil Ali-Jackson

A named executive officer of Aclaris Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$4,687,106

Salary $391,400Stock awards $683,304

FY2020: $768,042

3rd of 5 named executive officers at Aclaris Therapeutics by FY2021 total.

5 named officers on file for Aclaris Therapeutics, FY2021

Kamil Ali-Jackson’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • ACRS’s disclosed peer group of 43 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aclaris Therapeutics’s whole pay program stands against its peers

  • Aclaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2022 (DEF 14A).

Free

Get Kamil Ali-Jackson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kamil Ali-Jackson compensation by year

Aclaris Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Aclaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$380,000$391,400
Bonus$0$0
Stock awards$117,089$683,304
Option awards$84,285$1,606,689
Non-equity incentive$174,800$0
Pension and deferred compensation$0$0
All other$11,868$2,005,713
Total$768,042$4,687,106

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 21, 2022, accession 0001558370-22-005681, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-22-005681. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2022.

$768K
$4.7M
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU34,350$499,449—
RSU28,400$412,936—
RSU19,914$289,550—
RSU3,875$56,343—
Option69,696—$1.26
Option13,500—$22.09
Option99,500—$24.06

Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Aclaris Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Neal WalkerChief Executive Officer$6,854,936
Joseph MonahanChief Scientific Officer$5,327,305
Kamil Ali-Jackson · this pageFormer Chief Legal Officer$4,687,106
Frank RuffoChief Financial Officer$3,262,768
David GordonFormer Chief Medical Officer$2,921,109

The full Aclaris Therapeutics compensation record

free company brief

This page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aclaris Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kamil Ali-Jackson's compensation dossier · One-time report. No refunds.